BCART — Biocartis NV Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.6% | ||
| Return on Equity | n/a | ||
| Operating Margin | -71.24% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 27.81 | 37.44 | 43.13 | 48.27 | 57.48 | 58 | 76 | 22.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Directors
- Christian Reinaudo CHM (66)
- Herman Verrelst CEO (47)
- Jean-Marc Roelandt CFO (56)
- Piet Houwen COO (53)
- Roald Borre NED (48)
- Luc Gijsens NID (67)
- Christine Kuslich NID (53)
- Ann-Christine Sundell NID (56)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- November 24th, 2014
- Public Since
- April 27th, 2015
- No. of Employees
- 526
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 93,915,910
- Address
- Generaal de Wittelaan 11B, MALINES (MECHELEN), 2800
- Web
- https://biocartis.com/
- Phone
- +32 15632600
- Contact
- Renate Degrave
- Auditors
- Deloitte Bedrijfsrevisoren
Upcoming Events for BCART
Similar to BCART
Agfa Gevaert NV
Euronext - Brussels
Ion Beam Applications SA
Euronext - Brussels
Nyxoah SA
Euronext - Brussels
Onward Medical NV
Euronext - Brussels
FAQ
As of Today at 19:35 UTC, shares in Biocartis NV are trading at €0.29. This share price information is delayed by 15 minutes.
Shares in Biocartis NV last closed at €0.29 and the price had moved by -67.08% over the past 365 days. In terms of relative price strength the Biocartis NV share price has underperformed the FTSE Global All Cap Index by -67.91% over the past year.
The overall consensus recommendation for Biocartis NV is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiocartis NV does not currently pay a dividend.
Biocartis NV does not currently pay a dividend.
Biocartis NV does not currently pay a dividend.
To buy shares in Biocartis NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.29, shares in Biocartis NV had a market capitalisation of .
Here are the trading details for Biocartis NV:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: BCART
Based on an overall assessment of its quality, value and momentum Biocartis NV is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocartis NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -54.03%.
As of the last closing price of €0.29, shares in Biocartis NV were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biocartis NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biocartis NV's management team is headed by:
- Christian Reinaudo - CHM
- Herman Verrelst - CEO
- Jean-Marc Roelandt - CFO
- Piet Houwen - COO
- Roald Borre - NED
- Luc Gijsens - NID
- Christine Kuslich - NID
- Ann-Christine Sundell - NID